Targeting stroma to treat cancers

被引:59
作者
Engels, Boris [1 ]
Rowley, Donald A. [1 ]
Schreiber, Hans [1 ]
机构
[1] Univ Chicago, Dept Pathol, Comm Canc Biol, Comm Immunol, Chicago, IL 60637 USA
关键词
Tumor stroma; Tumor promotion; Cancer therapy; Relapse; Eradication; REGULATORY T-CELLS; COLONY-STIMULATING FACTOR; MESENCHYMAL STEM-CELLS; TUMOR-DERIVED EXOSOMES; BONE-MARROW; BREAST-CANCER; MYELOID CELLS; SUPPRESSOR-CELLS; DENDRITIC CELLS; LUNG-CANCER;
D O I
10.1016/j.semcancer.2011.12.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
All cancers depend on stroma for support of growth. Leukemias, solid tumors, cancer cells causing effusions, metastases as well as micro-disseminated cancer cells release factors that stimulate stromal cells, which in turn produce ligands that stimulate cancer cells. Therefore, elimination of stromal support by destroying the stromal cells or by inhibiting feedback stimulation of cancer growth is in the focus of many evolving therapies. A stringent evaluation of the efficacy of stromal targeting requires testing in animal models. Most current studies emphasize the successes of stromal targeting rather than deciphering its limitations. Here we show that many of the stromal targeting approaches, while often reducing tumor growth rates, are rarely curative. Therefore, we will also discuss conditions where stromal targeting can eradicate large established tumors. Finally, we will examine still unanswered questions of this promising and exciting area of cancer research. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:41 / 49
页数:9
相关论文
共 185 条
[1]   The hematopoietic stem cell in its place [J].
Adams, GB ;
Scadden, DT .
NATURE IMMUNOLOGY, 2006, 7 (04) :333-337
[2]   Molecular characterization of the tumor microenvironment in breast cancer [J].
Allinen, M ;
Beroukhim, R ;
Cai, L ;
Brennan, C ;
Lahti-Domenici, J ;
Huang, HY ;
Porter, D ;
Hu, M ;
Chin, L ;
Richardson, A ;
Schnitt, S ;
Sellers, WR ;
Polyak, K .
CANCER CELL, 2004, 6 (01) :17-32
[3]   CD4+FoxP3+ regulatory T cells confer infectious tolerance in a TGF-β-dependent manner [J].
Andersson, John ;
Tran, Dat Q. ;
Pesu, Marko ;
Davidson, Todd S. ;
Ramsey, Heather ;
O'Shea, John J. ;
Shevach, Ethan M. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2008, 205 (09) :1975-1981
[4]   Malignant effusions and immunogenic tumour-derived exosomes [J].
Andre, F ;
Schartz, NEC ;
Movassagh, M ;
Flament, C ;
Pautier, P ;
Morice, P ;
Pomel, C ;
Lhomme, C ;
Escudier, B ;
Le Chevalier, T ;
Tursz, T ;
Amigorena, S ;
Raposo, G ;
Angevin, E ;
Zitvogel, L .
LANCET, 2002, 360 (9329) :295-305
[5]  
[Anonymous], J LEUKOC BIOL
[6]  
[Anonymous], 1907, Z FUER KREBSFORSCH
[7]   CD169-Positive Macrophages Dominate Antitumor Immunity by Crosspresenting Dead Cell-Associated Antigens [J].
Asano, Kenichi ;
Nabeyama, Ami ;
Miyake, Yasunobu ;
Qiu, Chun-Hong ;
Kurita, Ai ;
Tomura, Michio ;
Kanagawa, Osami ;
Fujii, Shin-ichiro ;
Tanaka, Masato .
IMMUNITY, 2011, 34 (01) :85-95
[8]  
Aschoff L., 1924, Ergb Inn Med. Kinderheilk, V26, P1, DOI [DOI 10.1007/978-3-642-90639-8_1, 10.1007/978-3-642-90639-8_1]
[9]  
BALDUCCI L, 1983, CANCER RES, V43, P4643
[10]   T Cells and Stromal Fibroblasts in Human Tumor Microenvironments Represent Potential Therapeutic Targets [J].
Barnas, Jennifer L. ;
Simpson-Abelson, Michelle R. ;
Yokota, Sandra J. ;
Kelleher, Raymond J., Jr. ;
Bankert, Richard B. .
CANCER MICROENVIRONMENT, 2010, 3 (01) :29-47